Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gazyvaro Targeting Tumor-Promoting Regulatory B-Cells in Solid Tumors (Melanoma Cohort)
2019-000914-12Phase 2Terminated
- Sponsor
- University of Cologne
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in melanoma, sponsored by University of Cologne. Primary endpoint: Disease control rate. Started Jan 2020; status: terminated.
02
Drugs
obinutuzumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2019-000914-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000914-12.